Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Vanguard International High Dividend Yield ETF trades at $100.82. The key difference: Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | VYMI | |
|---|---|---|
Market Cap | $89.27M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $2.87 | $101.60 |
52-Week Low | $1.05 | $79.95 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
VYMI trades at $100.23, down 0.65% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX 6-day at 60.71). The ETF offers a forward dividend of $1.26 payable June 23, 2026. Recent news highlights its role in diversifying away from U.S. tech, with Vanguard research suggesting international stocks may outperform over the next decade.
Outlook remains positive given its low 0.07% expense ratio, high dividend yield, and diversification benefits. Risks include currency fluctuations and global economic volatility. Analyst sentiment is favorable, emphasizing sustainable dividends and attractive valuations relative to U.S. markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
